<p>Survival curves representing the outcome of the bacterial challenge. N = 30 for each group, except AlphaJect 3000 (N = 28). The two vaccinated groups showed significantly higher survival than infected controls (P = 0.001 and 0.01 for experimental vaccine and AlphaJect 3000, respectively), as well as their respective adjuvants (P = 0.0001 and 0.02 for experimental vaccine and AlphaJect 3000, respectively). Asterisks indicate statistically significant difference between treated group and infected controls (* = P<0.05, ** = P<0.01).</p
<p>Kaplan-Meier survival curves for adult-primed (A) or infant-primed (B) mice immunized with 1, 2, ...
<p>30 days after bacterial challenge survival rates are the following: continuous therapy 91.53%, op...
<p>Kaplan-Meier survival curves for adult-primed or infant-primed mice immunized with 3 doses of eit...
<p>Survival curves for control (N = 18) and LPS pretreated mice (N = 29) following intravenous bacte...
<p>198 day post-vaccination, vaccinees receiving SAG2 in 10<sup>8</sup> per dose (Group 2) and contr...
<p>Vaccinated and mock-vaccinated mice in challenge groups were challenged thorough the intra-vagina...
<p>Survival curves for LPS pretreated and PBS control (A) A/J, (B) CBA/CaHN-Btk<sup>xid/</sup>/J, an...
<p>Survival curves for patients with neutrophil respiratory burst <19.8% (n = 69, solid line) and ≥1...
<p>Kaplan-Meier survival curves for adult mice immunized with 1 or 2 doses of PBS (black squares) or...
<p>Kaplan-Meier survival curves for adult-primed mice immunized with 3 doses of either PBS (black sq...
<p>The Kaplan-Meier survival curve of patients infected by community-associated MRSA (solid line) is...
Evolution of the bacterial population (log10 CFU/mL) for the MSSA (A and B) and MRSA (C and D) strai...
<p>* indicates significance vs. uninfected group (*P<0.05, **P<0.01), & indicates significance vs. n...
<p>A) Survival curves (fitted for all data from round 1 and round 2) are shown for mice infected wit...
<p>(A) An ELISA was performed to measure the mean reciprocal titer of circulating anti-MARV GP IgG f...
<p>Kaplan-Meier survival curves for adult-primed (A) or infant-primed (B) mice immunized with 1, 2, ...
<p>30 days after bacterial challenge survival rates are the following: continuous therapy 91.53%, op...
<p>Kaplan-Meier survival curves for adult-primed or infant-primed mice immunized with 3 doses of eit...
<p>Survival curves for control (N = 18) and LPS pretreated mice (N = 29) following intravenous bacte...
<p>198 day post-vaccination, vaccinees receiving SAG2 in 10<sup>8</sup> per dose (Group 2) and contr...
<p>Vaccinated and mock-vaccinated mice in challenge groups were challenged thorough the intra-vagina...
<p>Survival curves for LPS pretreated and PBS control (A) A/J, (B) CBA/CaHN-Btk<sup>xid/</sup>/J, an...
<p>Survival curves for patients with neutrophil respiratory burst <19.8% (n = 69, solid line) and ≥1...
<p>Kaplan-Meier survival curves for adult mice immunized with 1 or 2 doses of PBS (black squares) or...
<p>Kaplan-Meier survival curves for adult-primed mice immunized with 3 doses of either PBS (black sq...
<p>The Kaplan-Meier survival curve of patients infected by community-associated MRSA (solid line) is...
Evolution of the bacterial population (log10 CFU/mL) for the MSSA (A and B) and MRSA (C and D) strai...
<p>* indicates significance vs. uninfected group (*P<0.05, **P<0.01), & indicates significance vs. n...
<p>A) Survival curves (fitted for all data from round 1 and round 2) are shown for mice infected wit...
<p>(A) An ELISA was performed to measure the mean reciprocal titer of circulating anti-MARV GP IgG f...
<p>Kaplan-Meier survival curves for adult-primed (A) or infant-primed (B) mice immunized with 1, 2, ...
<p>30 days after bacterial challenge survival rates are the following: continuous therapy 91.53%, op...
<p>Kaplan-Meier survival curves for adult-primed or infant-primed mice immunized with 3 doses of eit...